Baseline patient demographics
| . | 10 mg bid (N = 6) . | 15 mg bid (N = 3) . | 25 mg bid (N = 6) . | 50 mg bid (N = 6) . | Total (N = 21) . |
|---|---|---|---|---|---|
| Age, median (range), y | 62.0 (58.0-74.0) | 63.0 (58.0-79.0) | 66.5 (48.0-81.0) | 72.0 (56.0-88.0) | 63.0 (48.0-88.0) |
| Female/male, n (%) | 3 (50.0)/3 (50.0) | 1 (33.3)/2 (66.7) | 2 (33.3)/4 (66.7) | 2 (33.3)/4 (66.7) | 8 (38.1)/13 (61.9) |
| ECOG 0-1, n (%) | 3 (50.0) | 3 (100.0) | 5 (83.3) | 4 (66.7) | 15 (71.4) |
| ECOG 2-3, n (%) | 3 (50.0) | — | 1 (16.7) | 2 (33.3) | 6 (28.6) |
| Disease duration before therapy, median (range), mo | 137.8 (14.3-408.0) | 114.6 (24.7-116.6) | 168.1 (0.8-360.2) | 27.0 (1.5-148.6) | 85.3 (0.8-408.0) |
| Accelerated phase, n (%) | 2 (33.3) | — | 3 (50.0) | 3 (50.0) | 8 (38.1) |
| Blast phase, n (%) | 4 (66.7) | 3 (100.0) | 3 (50.0) | 3 (50.0) | 13 (61.9) |
| Spleen by palpation, median (range) | 13 (0-19) | 6 (6-6) | 8.5 (0-15) | 0 (0-13) | 6 (0-19) |
| Prior ruxolitinib, n (%) | 2 (33.3) | — | 1 (16.7) | 3 (50.0) | 6 (28.6) |
| Prior decitabine, n (%) | 1 (16.7) | 2 (66.7) | 2 (33.3) | — | 5 (23.8) |
| Prior HSCT, n (%) | — | — | 1 (16.7) | — | 1 (4.8) |
| . | 10 mg bid (N = 6) . | 15 mg bid (N = 3) . | 25 mg bid (N = 6) . | 50 mg bid (N = 6) . | Total (N = 21) . |
|---|---|---|---|---|---|
| Age, median (range), y | 62.0 (58.0-74.0) | 63.0 (58.0-79.0) | 66.5 (48.0-81.0) | 72.0 (56.0-88.0) | 63.0 (48.0-88.0) |
| Female/male, n (%) | 3 (50.0)/3 (50.0) | 1 (33.3)/2 (66.7) | 2 (33.3)/4 (66.7) | 2 (33.3)/4 (66.7) | 8 (38.1)/13 (61.9) |
| ECOG 0-1, n (%) | 3 (50.0) | 3 (100.0) | 5 (83.3) | 4 (66.7) | 15 (71.4) |
| ECOG 2-3, n (%) | 3 (50.0) | — | 1 (16.7) | 2 (33.3) | 6 (28.6) |
| Disease duration before therapy, median (range), mo | 137.8 (14.3-408.0) | 114.6 (24.7-116.6) | 168.1 (0.8-360.2) | 27.0 (1.5-148.6) | 85.3 (0.8-408.0) |
| Accelerated phase, n (%) | 2 (33.3) | — | 3 (50.0) | 3 (50.0) | 8 (38.1) |
| Blast phase, n (%) | 4 (66.7) | 3 (100.0) | 3 (50.0) | 3 (50.0) | 13 (61.9) |
| Spleen by palpation, median (range) | 13 (0-19) | 6 (6-6) | 8.5 (0-15) | 0 (0-13) | 6 (0-19) |
| Prior ruxolitinib, n (%) | 2 (33.3) | — | 1 (16.7) | 3 (50.0) | 6 (28.6) |
| Prior decitabine, n (%) | 1 (16.7) | 2 (66.7) | 2 (33.3) | — | 5 (23.8) |
| Prior HSCT, n (%) | — | — | 1 (16.7) | — | 1 (4.8) |
bid, twice daily.